Added to YB: 2025-10-27
Pitch date: 2025-09-09
IMRX [bullish]
Immuneering Corporation
-21.15%
current return
Author Info
No bio for this author
Company Info
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients.
Market Cap
$338.3M
Pitch Price
$7.99
Price Target
25.00 (+297%)
Dividend
N/A
EV/EBITDA
-5.03
P/E
-2.85
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Immuneering Corporation - $IMRX
IMRX: $5.95/share, $247M mcap. June 2025 pancreatic cancer data exceptional vs historical controls. Sept update adding 3mo data should confirm 6-9mo survival rates, driving 2-4x pop to $10-25. Breakthrough designation likely. $200-400 price target in 2-3yrs on $10B+ 1st line standard of care opportunity (~50K US patients, $5B+ market).
Read full article (5 min)